NVIDIA-Backed Iambic Therapeutics Files for IPO on Nasdaq
NVDA sits 38% above its 52-week low of $164.27.
Summary
Iambic Therapeutics, an AI-driven drug discovery company in which NVIDIA holds a 9.6 million share pre-IPO stake, has filed for an initial public offering on the Nasdaq Global Select Market under the ticker 'IAM'. The offering is underwritten by J.P. Morgan, Jefferies, BofA Securities, and Citigroup. Iambic reported collaboration revenue of $12.8 million and a net loss of $50.1 million for the six months ended June 30, 2026. For NVIDIA, this represents a strategic investment in the AI-enabled biotech space, though the financial impact is modest relative to its $5.5 trillion market cap. The IPO could provide a liquidity event for NVIDIA's stake and signals continued expansion of its AI ecosystem beyond core semiconductor markets.
At the time of this announcement, NVDA was trading at $226.90 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $5.5T. The 52-week trading range was $164.27 to $236.54. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: Reuters.